Vaccine Info

mRNA-1010 Quadrivalent Influenza Vaccine

Authored by
Staff
Last reviewed
August 5, 2022
Share

mRNA-1010 Quadrivalent Influenza Vaccine Description

Moderna, Inc.'s mRNA-1010 Quadrivalent Influenza Vaccine candidate is targeting WHO recommendations. The quadrivalent mRNA-1010 vaccine encodes for the hemagglutinin (HA) protein from four seasonal influenza viruses based on the recommendations of the World Health Organization, including seasonal influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.

mRNA-1010 is Moderna's first seasonal influenza mRNA vaccine candidate to enter the clinic, says the Company. mRNA medicines take advantage of normal biological processes to express proteins and create a desired therapeutic effect. This enables the potential treatment of a broad spectrum of diseases, many of which cannot be addressed with current technologies.

Positive interim data from the Phase 1 study of the Company's quadrivalent seasonal flu vaccine candidate, mRNA-1010, was announced on December 10, 2021. In the study, mRNA-1010 successfully boosted hemagglutination inhibition assay geometric mean titers against all strains 29 days after vaccination at doses tested in younger and older adults. 

The Phase 2 study of mRNA-1010 was initiated in November 2021 to confirm dose across three levels, including a lower 25 µg dose level and the two lowest dose levels from Phase 1 (50 µg and 100 µg) with approximately 150 participants per arm. In addition, the Phase 2 study includes an approved flu vaccine comparator arm (N=50). The Phase 2 study was fully enrolled in November (N=500), and an interim analysis is expected in early 2022.

Preparation for the Phase 3 study for mRNA-1010 is already underway, including manufacturing. The Company seeks guidance from global regulatory agencies on the Phase 3 program.

Moderna is also developing two next-generation flu candidates that incorporate neuraminidase antigens to improve immunity by increasing immunologic breadth by targeting more conserved antigens (mRNA-1020, mRNA-1030). Moderna started its Phase 1/2 study of mRNA-1020 and mRNA-1030 in April 2022.

One pillar of Moderna's vaccine strategy is to develop a pan-respiratory annual booster vaccine, which the Company believes could be the first to market with a COVID + Flu + RSV booster vaccine. A pan-respiratory annual single booster vaccine to cover multiple viruses could create value for the healthcare system through compliance, convenience to the customer (one vs. three injections), and reduction in vaccine administration cost.

Cambridge, MA-based Moderna's mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability, which may position the Company as a leader in preparing for and responding to infectious disease threats that place millions of people at risk around the world. There are currently nine prophylactic mRNA vaccines in our development pipeline, with seven Phase 1 studies underway. To learn more, visit www.modernatx.com.

mRNA-1010 Indication

mRNA-1010 Quadrivalent Influenza Vaccine is indicated to prevent seasonal influenza.

mRNA-1010 Dosage

In the Phase 1 study, mRNA-1010 was evaluated at 50 µg, 100 µg, and 200 µg dose levels in younger adult (age 18-49) and older adult (age 50+) cohorts. A minimal dose-response was observed between the 50 µg, 100 µg, and 200 µg dose levels. No significant safety findings were observed through day 29.

At the lowest dose level (50 µg) in younger adults, Day 29 geometric mean titers (GMT) against influenza A strains were 538 (H1N1) and 530 (H3N2); GMT against influenza B strains were 467 (B/Yamagata) and 261 (B/Victoria). Geometric mean fold-rises (GMFR) above baseline for influenza A strains were approximately 10-fold (H1N1) and 8-fold (H3N2), and about 3-fold for B/Yamagata and 2-fold for B/Victoria. A minimal dose-response was observed between the 50 µg, 100 µg, and 200 µg dose levels, suggesting the potential to explore even lower doses.

At the lowest dose level (50 µg) in older adults, Day 29 GMT against influenza A strains were 310 (H1N1) and 263 (H3N2); GMT against influenza B strains were 305 (B/Yamagata) and 215 (B/Victoria). GMFR for influenza A strains were approximately 6-fold (H1N1) and 6-fold (H3N2), approximately 3-fold for B/Yamagata and 2-fold for B/Victoria.

mRNA-1010 Side Effects

Adverse reactions were reported more frequently in younger adults compared to older adults and at higher dose levels in the phase 1 study. The most common solicited local responses for both age groups included pain and axillary swelling/tenderness. The most common solicited systemic ARs for both age groups included fatigue, arthralgia, myalgia, and headache.

Moderna's Two New Development Candidates

Moderna announced two beyond quadrivalent vaccine candidates on December 10, 2021, which the Company believes offer the opportunity to expand strain coverage and enhance tools available to public health authorities when selecting antigens. mRNA-1011 will have one additional hemagglutinin (HA) antigen, and mRNA-1012 will have two other HA antigens. Separately, the Company previously announced that it is also developing two next-generation flu candidates that incorporate neuraminidase antigens to broaden immunity beyond hemagglutinin (mRNA-1020, mRNA-1030).

mRNA-1010 News

August 3, 2022 - Moderna Inc. reported the Phase 3 safety and immunogenicity trial started in June 2022 in the Southern Hemisphere for seasonal flu vaccine candidate (mRNA-1010) to support potential accelerated approval. The Company is preparing for a Phase 3 efficacy study in the fall of 2022 (if needed).

June 7, 2022 - Moderna, Inc. announced the first participants had been dosed in a Phase 3 study of the Company's seasonal influenza vaccine candidate mRNA-1010.

May 4, 2022 - The Company announced first quarter 2022 revenues of $6.1 billion and GAAP net income of $3.7 billion.

March 14, 2022 - An analysis - Moderna and Novavax's combination vaccine candidate draws expert enthusiasm for efficacy owing to the former's mRNA vaccine technology and the latter's noninferior data for its standalone protein subunit flu vaccine, which is conducting a phase 1/2 clinical study.

December 10, 2021 - Moderna, Inc. announced the first positive interim data from the Phase 1 study of the Company's quadrivalent seasonal flu vaccine candidate, mRNA-1010. In the study, mRNA-1010 successfully boosted hemagglutination inhibition assay geometric mean titers against all strains 29 days after vaccination at doses tested in younger and older adults. The Company also announced that the Phase 2 study of mRNA-1010 is now fully enrolled, and the preparation for the Phase 3 study is underway. In addition, Moderna also updated its seasonal flu vaccine program, announcing two beyond quadrivalent seasonal flu development candidates (mRNA-1011 and mRNA-1012).

November 4, 2021 - Moderna provided updates on several of its products. "We look forward to sharing data from the Phase 1 study of our flu vaccine candidate soon, and we are preparing to start our Phase 2 study. Phase 1 portion of the Phase 1/2 study of quadrivalent seasonal flu vaccine candidate (mRNA-1010) fully enrolled, preparations for Phase 2 portion of the study are ongoing."

July 7, 2021 - Moderna Announces First Participant Dosed in Phase 1/2 Study of Its Quadrivalent Seasonal Flu mRNA Vaccine. This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010, Moderna's seasonal influenza vaccine candidate, in healthy adults 18 years and older in the U.S. The Company intends to enroll approximately 180 participants in the study. mRNA-1010 is Moderna's first seasonal influenza vaccine candidate to enter the clinic. It targets lineages the World Health Organization (WHO) recommended to prevent influenza, including seasonal influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.

January 11, 2021 - Moderna, Inc. revealed in a press release influenza vaccine candidates (mRNA-1010, mRNA-1020, mRNA-1030). This first-generation flu program will evaluate multiple candidates comprising multiple antigen combinations against the four seasonal viruses recommended by the WHO. Phase 1 clinical trials for the program are expected to begin in 2021.

mRNA-1010 Clinical Trials

The Phase 3 randomized, observer-blind study is designed to evaluate the safety and immunological non-inferiority of mRNA-1010 to a licensed seasonal influenza vaccine in adults 18 years and older. Participants will be randomly assigned on a 1:1 ratio to receive either a single dose of mRNA-1010 or a single dose of a licensed seasonal influenza vaccine as a comparator.

This Phase 1/2 randomized, stratified, observer-blind, dose-ranging study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010, Moderna's seasonal influenza vaccine candidate, in healthy adults 18 years and older in the U.S. The Company intends to enroll approximately 180 participants in the study. The Phase 2 study of mRNA-1010 was initiated in November to confirm dose across three dose levels, including a lower 25 µg dose level and the two lowest dose levels from Phase 1 (50 µg and 100 µg) with approximately 150 participants per arm. In addition, the Phase 2 study includes an approved flu vaccine comparator arm (N=50). The Phase 2 study was fully enrolled in November (N=500), and an interim analysis is expected in early 2022. Preparation for the Phase 3 study for mRNA-1010 is already underway, including manufacturing. The Company seeks guidance from global regulatory agencies on the Phase 3 program.